Phase I study of phenylacetate administered twice daily to patients with cancer.

@article{Thibault1995PhaseIS,
  title={Phase I study of phenylacetate administered twice daily to patients with cancer.},
  author={Alain A Thibault and Dvorit Samid and Michael R. Cooper and William D. Figg and Anne C. Tompkins and Nicholas Patronas and Donna J. Headlee and David D. R. Kohler and David J Venzon and Charles E. Myers},
  journal={Cancer},
  year={1995},
  volume={75 12},
  pages={2932-8}
}
BACKGROUND The growth-inhibiting and differentiating effects of sodium phenylacetate against hematopoietic and solid tumor cell lines has aroused clinical interest in its use as an anticancer drug. In an earlier Phase I trial of phenylacetate aimed at maintaining serum drug concentrations in the range that proved active in vitro (> 250 micrograms/ml) for 2… CONTINUE READING